Novartis and Ionis cholesterol drug fails to hit goal in late-stage trial

Novartis and Ionis's late-stage trial of their cholesterol-lowering drug came up short of its goal, according to reports on the readout. The miss is a setback for the two companies' bet on the cardiovascular candidate.

Detected & updated continuously · Source: Nebula